Vitamin D and innate immunity

Vitamin D

Volumn , Issue , 2011, Pages 1777-1787

  White, John H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884748030     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10091-5     Document Type: Chapter

References (127)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
2. Akira S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunol. Rev. 2009, 227:5-8.
3. Irazoqui J.E., Urbach J.M., Ausubel F.M. Evolution of host innate defence: insights from Caenorhabditis elegans and primitive invertebrates. Nature Rev. Immunol. 2010, 10:47-58.
4. Lai Y.P., Gallo R.L. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009, 30:131-141.
5. Masten A.R. Sunlight in tuberculosis. Chest 1935, 1:8-23.
6. Guy R.A. The history of cod liver oil as a remedy. Am. J. Dis. Child. 1923, 26:112-116.
7. Unraveling the enigma of vitamin D. Beyond Discovery, National Academy of Sciences, USA. http://www.beyonddiscovery.org/Includes/DBLink.asp?ID=.
8. Grad R. Cod and the consumptive: a brief history of cod-liver oil in the treatment of pulmonary tuberculosis. Pharm. Hist. 2004, 46:106-120.
9. Martineau A.R., Honecker F.U., Wilkinson R.J., Griffiths C.J. Vitamin D in the treatment of pulmonary tuberculosis. J. Ster. Biochem. Mol. Biol. 2007, 103:793-798.
10. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006, 84:18-28.
11. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo. Clin. Proc. 2006, 81:353-373.
12. Holick M.F. Vitamin D deficiency. New Engl. J. Med. 2007, 357:266-281.
13. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 1997, 7:439-443.
14. Holick M.F., Siris E.S., Binkley N., Beard M.K., Khan A., Katzer J.T., et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J. Clin. Endocrinol. Metab. 2005, 90:3215-3224.
15. Holick M.F. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest. 2006, 116:2062-2072.
16. Matsuoka L.Y., Wortsman J., Haddad J.G., Kolm P., Hollis B.W. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch. Dermatol. 1991, 127:536-538.
17. Nesby-O'Dell S., Scanlon K.S., Cogswell M.E., Gillespie C., Hollis B.W., Looker A.C., et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr. 2002, 76:187-192.
18. Schwalfenberg G. Not enough vitamin D for Canadians. Can. Fam. Physician. 2007, 53:841-854.
19. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
20. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Imm. Mechan. Dis. Ann. New York Acad. Sci. 2003, 987:258-261.
21. Brown S.J. The role of vitamin D in multiple sclerosis. Ann. Pharmacother. 2006, 40:1158-1161.
22. Adorini L., Penna G. Control of autoimmun diseases by the vitamin D system. Nature Clin. Pract. Rheumatol. 2008, 4:404-412.
23. Lin R., White J.H. The pleiotropic actions of vitamin D. BioEssays 2004, 26:21-28.
24. Davies P.D.O., Brown R.C., Woodhead J.S. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax 1985, 40:187-190.
25. Grange J.M., Davies P.D.O., Brown R.C., Woodhead J.S., Kardjito T. A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis. Tubercle 1985, 66:187-191.
26. Wilkinson R.J., Llewelyn M., Toossi Z., Patel P., Pasvol G., Lalvani A., et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis amongst Gujarati Asians in West London: a case-control study. Lancet 2000, 355:618-621.
27. Rook G.A., Steele J., Fraher L., Barker S., Karmali R., O'Riordan J., et al. Vitamin D3, interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunol. 1986, 57:159-163.
28. Liu P.T., Stenger S., Tang D.H., Modlin R.L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 2007, 179:2060-2063.
29. Liu P.T., Stenger S., Li H.Y., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311. 1770-1173.
30. Liu P.T., Krutzik S.R., Modlin R.L. Therapeutic implications of the TLR and VDR partnership. Trend. Mol. Med. 2007, 13:117-124.
31. Martineau A.R., Wilkinson R.J., Wilkinson K.A., Newton S.M., Kampmann B., Hall B.M., et al. A single dose of vitamin D enhances immunity to mycobacteria. Am. J. Resp. Crit. Care Med. 2007, 176:208-213.
32. Nursyam E.W., Amin Z., Rumende C.M. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta. Med. Indones. 2006, 38:3-5.
33. Wejse C., Gomes V.F., Rabna P., Gustafson P., Aaby P., Lisse I.M., et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2009, 179:843-850.
34. Kawarau A., Takeda E., Tanida N., Nakagawa K., Yamamoto H., Sawada K., et al. Inhibitory effect of long term 1 alpha-hydroxyvitamin D3 administration on Helicobacter pylori infection. J. Clin. Biochem. & Nutr. 2006, 38:103-106.
35. Bischoff-Ferrari H.A., Dawson-Hughes B., Platz A., Orav E.J., Stähelin H.B., Willett W.C., et al. Arch. Intern. Med. 2010, in press.
36. Brook I. Microbiology and antimicrobial management of sinusitis. J. Laryngol. Otol. 2005, 119:251-258.
37. Montone K.T. Infectious diseases of the head and neck: a review. Am. J. Clin. Pathol. 2007, 128:35-67.
38. Hughes D.A., Norton R. Vitamin D and respiratory health. Clin. Exper. Immunol. 2009, 158:20-25.
39. Wayse V., Yousafzai A., Mogale K., Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. Eur. J. Clin. Nutr. 2004, 58:563-567.
40. Muhe L., Lulseged S., Mason K.E., Simoes E.A.F. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet 1997, 349:1801-1804.
41. Laaksi I., Ruohola J.-P., Tuohimaa P., Auvinen A., Haataja R., Pihlajamäki H., et al. An association of serum vitamin D concentrations <40nmol/L with acute respiratory tract infection in young Finnish men. Am. J. Clin. Nutr. 2007, 86:714-717.
42. Cannell J.J., Vieth R., Umhau J.C., Holick M.F., Grant W.B., Madronich S., et al. Epidemic influenza and vitamin D. Epidemiol. Infect. 2006, 134:1129-1140.
43. Cannell J.J., Zasloff M., Garland C.F., Scragg R., Giovannucci E. On the epidemiology of influenza. Virol. J. 2008, 5. Art 29.
44. Urashima M., Segawa T., Okazaki M., Kurihara M., Ida H. Am. J. Clin. Nutr. 2010, doi: 10.3945/ajcn.2009.29094.
45. Li-Ng M., Aloia J.F., Pollack S., Cunha B.A., Mikhail M., Yeh J., et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol. Infect. 2009, 137:1396-1404.
46. Wasserman P., Rubin D.S. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS Apr. 2010, 8.
47. Mueller N.J., Fux C.A., Ledergerber B., Elzi L., Schmid P., Dang T., et al. The Swiss HIV Cohort Study. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naïve and successfully treated Swiss HIV patients. AIDS Feb. 15 2010.
48. Bang U.C., Shakar S.A., Hitz M.F., Jespersen M.S., Andersen O., Nielsen S.D., et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand. J. Infect. Dis. 2010, 42:306-310.
49. Villamor E. A potential role for vitamin D on HIV infection?. Nutr. Rev. 2006, 64:226-233.
50. Mehta S., Giovannucci E., Mugusi F.M., Spiegelman D., Aboud S., Hertzmark E., et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One Jan. 19 2010, 5(1):e8770.
51. Mehta S., Hunter D.J., Mugusi F.M., Spiegelman D., Manji K.P., Giovannucci E.L., et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J. Infect. Dis. 2009, 200:1022-1030.
52. Uitterlinden A.G., Fang Y., van Meurs J.B.J., Pols H.A.P., van Leeuwen J.P.T.M. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338:143-156.
53. Chocano-Bedoya P., Ronnenberg A.G. Vitamin D and tuberculosis. Nutrition Rev. 2009, 67:289-293.
54. Gao L., Tao Y., Zhang L., Jin Q. Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. Int. J. Tuber. Lung Dis. 2010, 14:15-23.
55. Fitness J., Tosh K., Hill A.V.S. Genetics of susceptibility to leprosy. Genes Immun. 2002, 3:441-453.
56. Roy S., Frodsham A., Saha B., Hazra S.K., Mascie-Taylor C.G., Hill A.V.S. Association of vitamin D receptor genotype with leprosy type. J. Infect. Dis. 1999, 179:187-191.
57. Fitness J., Floyd S., Warndorff D.K., Sichali L., Mwaungulu L., Crampin A.C., et al. Large-scale candidate gene study of leprosy susceptibility in the Karonga district of northern Malawi. Am. J. Trop. Med. Hyg. 2004, 71:330-340.
58. Roth D.E., Jones A.B., Prosser C., Robinson J.L., Vohra S. Vitamin D receptor polymorphisms and the risk of acute lower respiratory tract infection in early childhood. J. Infect. Dis. 2008, 197:676-680.
59. Barber Y., Rubio C., Fernandez E., Rubio M., Fibla J. Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users. J. Infect. Dis. 2001, 184:1279-1288.
60. De la Torre M.S., Torres C., Nieto G., Vergara S., Carrero A.S., Macia J., et al. Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. J. Infect. Dis. 2008, 197:405-410.
61. Nevado J., SP Tenbaum Castillo A.I., Sanchez-Pacheco A., Aranda A. Activation of the human immunodeficiency virus type I long terminal repeat by 1 alpha,25-dihydroxyvitamin D3. J. Mol. Endocrinol. 2007, 38:587-601.
62. Bhalla A.K., Amento E.P., Serog B., Glimcher L.H. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J. Immunol. 1984, 133:1748-1754.
63. Brennan A., Katz D.R., Nunn J.D., Barker S., Hewison M., Fraher L.J., et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunol. 1987, 61:457-461.
64. Adorini L. Intervention in autoimmunity: The potential of vitamin D receptor agonists. Cell Immunol. 2005, 233:115-124.
65. White J.H. Vitamin D signaling, infectious diseases and regulation of innate immunity. Infect. Immun. 2008, 76:3837-3843.
66. Adams J.S., Sharma O.P., Gacad M.A., Singer F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J. Clin. Invest. 1983, 72:1856-1860.
67. Overbergh L., Decallonne B., Valckx D., Verstuyf A., Depovere J., Laureys J., et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin. Exp. Immunol. 2000, 120:139-146.
68. Overbergh L., Stoffels K., Waer M., Verstuyf A., Bouillon R., Mathieu C. Immune regulation of 25-hydroxyvitamin D-1 alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction. J. Clin. Endo. Metab. 2006, 91:3566-3574.
69. Stoffels K., Overbergh L., Giulietti A., Verlinden L., Bouillon R., Mathieu C. Immune regulation of 25-hydroxyvitamin-D-3-1 alpha-hydroxylase in human monocytes. J. Bone Min. Res. 2006, 21:37-47.
70. 3 of the NOD2/CARD15-beta defensin 2 innate immune pathway defective in Crohn's disease. J. Biol. Chem. 2010, 285:2227-2231.
71. Evans K.N., Taylor H., Zehnder D., Kilby M.D., Bulmer J.N., Shah F., et al. Increased expression of 25-hydroxyvitamin D-1 alpha-hydroxylase in dysgerminomas - a novel form of humoral hypercalcemia of malignancy. Am. J. Pathol. 2004, 165:807-813.
72. Evans K.N., Nguyen L., Chan J., Innes B.A., Bulmer J.N., Kilby M.D., et al. Effects of 25-hydroxyvitamin D-3 and 1,25-dihydroxyvitamin D-3 on cytokine production by human decidual cells. Biol. Reprod. 2006, 75:816-822.
73. Oberg F., Botlin J., Nilsson K. Functional antagonisms between vitamin-D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. J. Immunol. 1993, 150:3487-3495.
74. Schauber J., Dorschner R.A., Coda A.B., Büchau A.S., Liu P.T., Kiken D., et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 2007, 117:803-811.
75. Sadeghi K., Wessner B., Laggner U., Ploder M., Tamandl D., Friedl J., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 2006, 36:361-370.
76. White J.H. Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis. J. Ster. Biochem. Mol. Biol. 2004, 89-90C:239-244.
77. Lin R., Nagai Y., Sladek R., Bastien Y., Ho J., Petrecca K., et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 signaling on cell proliferation, differentiation and immune system regulation. Mol. Endocrinol. 2002, 16:1243-1256.
78. 3 target genes. Mol. Endocrinol. 2005, 19:2685-2695.
79. Wang T.T., Nestel F., Bourdeau V., Nagai Y., Wang Q., Wu J., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173:2909-2912.
80. Patil A., Hughes A.L., Zhang G. Rapid evolution and diversification of mammalian α-defensins as revealed by comparative analysis of rodent and primate genomes. Physiol. Genomics 2004, 20:1-11.
81. Hancock R.E.W., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnol. 2006, 24:1551-1557.
82. Doss M., White M.R., Tecle T., Hartshorn K.L. Human defensins and LL-37 in mucosal immunity. J. Leuk. Biol. 2010, 2010(87):79-92.
83. Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D-3. FASEB J. 2005, 19:1067-1077.
84. Weber G., Heilborn J.D., Chamorro Jimenez C.I., Hammarsjö A., Törmä H., Ståhle M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J. Invest. Dermatol. 2005, 124:1080-1082.
85. Voss E., Wehkamp J., Wehkamp K., Stange E.F., Schröder J.M., Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J. Biol. Chem. 2006, 281:2005-2011.
86. Liu P.T., Schenk M., Walker V.P., Dempsey P.W., Kanchanapoomi M., Wheelwright M., et al. Convergence of IL-1β and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 2009, 4:e5810.
87. Cho J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nature Rev. Immunol. 2008, 8:458-466.
88. Fellermann K., Stange D.E., Schaeffeler E., Schmalzl H., Wehkamp J., Bevins C.L., et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon, Am. J. Human. Genet. 2006, 79:439-448.
89. Lim W.-C., Hanauer S.B., Li Y.C. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nature Clin. Pract. Gastroenterol. Hepatol. 2005, 2:308-315.
90. Loftus E.V., Sandborn W.J. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. North Am. 2002, 31:1-20.
91. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterol. 2004, 126:1504-1517.
92. Zeng L., Anderson F.H. Seasonal change in the exacerbations of Crohn's disease. Scand. J. Gastroenterol. 1996, 31:79-82.
93. Lewis J.D., Aberra F.N., Lichtenstein G.R., Bilker W.B., Strom B.L. Seasonal variation in flares of inflammatory bowel disease. Gastroenterol. 2004, 126:665-673.
94. Aratari A., Papi C., Galletti B., Angelucci E., Viscido A., D'Ovidio V., et al. Seasonal variations in onset of symptoms in Crohn's disease. Digest. Liver Dis. 2006, 38:319-323.
95. Simmons J.D., Mullighan C., Welsh K.L., Jelwell D.P. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000, 47:211-214.
96. Smith A.M., Rahman F.Z., Bu'Hussain H., Graham S.J., Marks D.J.B., Sewell G.W., et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J. Exp. Med. 2009, 206.
97. Coulombe F., Behr M.A. Crohn's disease as an immune deficiency?. Lancet 2009, 374:769-770.
98. Coulombe F., Divangahi M., Veyrier F., de Leseleuc L., Gleason J.L., Yang Y.B., et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J. Exp. Med. 2009, 206:1709-1716.
99. Yuk J.M., Shin D.M., Lee H.M., Yang C.S., Jin H.S., Kim K.K., et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host. Microbe. 2009, 6:231-243.
100. Neta M.G., Joosten L.A. A NOD for autophagy. Nature Med. 2010, 16:28-30.
101. Wehkamp J., Schauber J., Stange E.F. Defensins and cathelicidins in gastrointestinal infections. Curr. Opin. Gastroenterol. 2007, 23:32-38.
102. Proud D., Sanders S.P., Wiehler S. Human rhinovirus infection induces airway epithelial cell production of human beta-defensin 2 both in vitro and in vivo. J. Immunol. 2004, 172:4637-4645.
103. Bergman P., Walter-Jallow L., Broliden K., Agerberth B., Soderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr. HIV Res. 2007, 5:410-415.
104. Steinstraesser L., Tippler B., Mertens L., Lamme E., Homann H.H., Lehnhardt M., et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirol. 2005, 2. Art 2.
105. Zanetti M. Cathelicidins: multifunctional peptides of the innate immunity. J. Leuk. Biol. 2004, 75:39-48.
106. Patil A., Hughes A.L., Zhang G. Rapid evolution and diversification of mammalian α-defensins as revealed by comparative analysis of rodent and primate genomes. Physiol. Genomics 2004, 20:1-11.
107. Gombart A.F., Saito T., Koeffler H.P. Expatiation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates. BMC Genomics 2009, 10:321. doi:10.1186/1471-2164-10-321.
108. Laperriere D., Wang T.T., White J.H., Mader S. Genome-wide mapping and function of consensus DR-type nuclear receptor hormone response elements in Alu repeats. BMC Genomics 2007, 8:23. doi:10.1186/1471-2164-8-23.
109. Segaert S., Simonart T. The epidermal vitamin D system and innate immunity: some more light shed on this unique photoendocrine system?. Dermatol. 2008, 217:7-11.
110. Carretero M., Escámez M.J., García M., Duarte B., Holguín A., Retamosa L., et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 2008, 128:223-236.
111. Dorschner R.A., Pestonjamasp V.K., Tamakuwala S., Ohtake T., Rudisill J., Nizet V., et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 2001, 117:91-97.
112. Heilborn J.D., Nilsson M.F., Kratz G., Weber G., Sørensen O., Borregaard N., et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 2003, 120:379-389.
113. Tokumaru S., Sayama K., Shirakata Y., Komatsuzawa H., Ouhara K., Hanakawa Y., et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol. 2005, 175:4662-4668.
114. Zasloff M. Sunlight, vitamin D, and the innate immune defenses of the human skin. J. Invest. Dermatol. 2005, 125:xvi-xvii.
115. Li M., Hener P., Zahang Z., Kato S., Metzger D., Chambon P. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc. Natl. Acad. Sci. USA 2006, 103:11736-11741.
116. Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Med. 2007, 13:975-980.
117. Peric M., Koglin S., Dombrowski Y., Gross K., Bradac E., Büchau A., et al. Vitamin D analogs differentially control antimicrobial peptide/"alarmin" expression in psoriasis. PLoS One 2009, 4(7):e6340.
118. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with anti-microbial peptide. Nature 2007, 449:563-568.
119. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., Wendum D., Firrincieli D., Coilly A., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterol. 2009, 136:1435-1443.
120. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
121. Peric M., Koglin S., Dombrowski Y., Groß K., Bradac E., Ruzicka T., et al. VDR and MEK-ERK dependent induction of the antimicrobial peptide cathelicidin in keratinocytes by lithocholic acid. Mol. Immunol. 2009, 46:3183-3187.
122. Yim S., Dhawan P., Ragunath C., Christakos S., Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J. Cyst. Fibros. 2007, 6:403-410.
123. Zehnder D., Evans K.N., Kilby M.D., Bulmer J.N., Innes B.A., Stewart P.M., et al. The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua. Am. J. Pathol. 2002, 161:105-114.
124. Evans K.N., Nguyen L., Chan J., Innes B.A., Bulmer J.N., Kilby M.D., et al. Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol. Reprod. 2006, 75:816-822.
125. Liu N., Kaplan A.T., Low J., Nguyen L., Liu G.Y., Equils O., et al. Vitamin D induces innate antibacterial responses in human trophoblasts via an intracrine pathway. Biol. Reprod. 2009, 80:398-406.
126. Muenz C. Enhancing immunity through autophagy. Ann. Rev. Immunol. 2009, 27:423-449.
127. Sorensen O.E., Follin P., Johnsen A.H., Calafat J., Tjabringa G.S., Hiemstra P.S., et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97:3951-3959.